The Female Health Company / Veru Healthcare Names Robert Getzenberg, Ph.D., as Executive Vice President of Clinical Developme...
April 11 2017 - 8:30AM
The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today
announced the appointment of Robert H. Getzenberg, Ph.D., as
Executive Vice President of Clinical Development.
Dr. Getzenberg will lead the clinical development of Veru’s
portfolio of drugs under development, including Tamsulosin DRS
(Tamsulosin HCl extended release for oral suspension) for the
treatment of benign prostatic hyperplasia (BPH), MSS-722 for male
infertility, APP-944 for hot flashes in men who are on hormonal
therapies for advanced prostate cancer, and APP-111 for prostate,
ovarian and breast cancers.
“Robert is eminently qualified to lead our product development
efforts,” said Mitchell Steiner, M.D., President and Chief
Executive Officer of The Female Health Company / Veru
Healthcare. “He is a highly regarded pharmaceutical executive
who also has made significant contributions as a scientific
researcher, investigator and tenured professor in the worlds of
urology, oncology and pharmacology. Notably, he brings
expertise in drug development for the treatment of BPH and prostate
cancer.”
Dr. Getzenberg, most recently served as Therapeutic Area Lead,
Prostate Cancer for GTx, Inc., where he was responsible for
advancing the company’s pipeline in prostate cancer, as well as
supporting efforts in Stress Urinary Incontinence (SUI) and breast
cancer. He previously spent 18 years as a faculty member of
the Johns Hopkins University School of Medicine and the University
of Pittsburgh School of Medicine. At Johns Hopkins, Dr.
Getzenberg served as co-director of the Prostate Cancer Program in
addition to his role as director of research for the Brady
Urological Institute and professor for the departments of urology,
oncology and pharmacology & molecular sciences. At the
University of Pittsburgh, he was director of research and
co-director of the Prostate and Urologic Cancer Center and
professor in the departments of pathology, medicine, pharmacology
and urology. Dr. Getzenberg is the recipient of a number of
awards including the 2000 University of Pittsburgh Chancellor’s
Distinguished Research Award and was selected as one of the “40
under 40” by Pittsburgh Magazine. Dr. Getzenberg has given
numerous international lectures related to his work, including the
first Donald Gleason Lecture at the University of Minnesota in 2012
and the Weisbach Lecture at the University of Michigan in 2007.
He has been the keynote speaker at urology and oncology
meetings in Japan, China and throughout Europe. Dr.
Getzenberg has and continues to serve in many leadership positions
in urology research, including as President of the Society of Basic
Urologic Research. Dr. Getzenberg has authored or co-authored
more than 165 peer-reviewed journal articles, book chapters and
reviews, and is an inventor on six awarded or pending patents.
Dr. Getzenberg completed his postdoctoral fellowship at the Yale
University School of Medicine. He earned a Ph.D. degree in
biochemistry, cellular & molecular biology from the Johns
Hopkins University School of Medicine and a bachelor of arts
degree, with high honors, in microbiology from Rutgers College,
Rutgers University.
About The Female Health Company / Veru
HealthcareThe Female Health Company / Veru Healthcare is a
pharmaceutical and medical device company, with a focus on the
development and commercialization of pharmaceuticals that qualify
for the FDA's 505(b)(2) accelerated regulatory approval pathway as
well as the 505(b)(1) pathway. The Company does business both
as "Veru Healthcare" and as "The Female Health Company" and is
organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which
develops and commercializes pharmaceutical products for men's and
women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices
Division, which is focused on commercializing sexual healthcare
products and devices for the consumer market, including the
Company's FC2 Female Condom® in the consumer health products sector
and PREBOOST® medicated individual wipe, which is a male genital
desensitizing drug product that helps in the prevention of
premature ejaculation.
- The Female Health Company manages the Global Public Health
Division, which is focused on the global public health sector FC2
business. This division markets the Company’s Female Condom
(FC2) to entities, including ministries of health, government
health agencies, U.N. agencies, nonprofit organizations and
commercial partners, that work to support and improve the lives,
health and well-being of women around the world.
More information about the Female Health Company and its
products can be found at www.femalehealth.com,
www.veruhealthcare.com and www.femalecondom.org. For
corporate and investor-related information about the Company,
please visit https://veruhealthcare.com/investors.
Contact:
Kevin Gilbert 312-366-2633
Veru (NASDAQ:VERU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Veru (NASDAQ:VERU)
Historical Stock Chart
From Apr 2023 to Apr 2024